CureVac N.V. Files 6-K Report
| Field | Detail |
|---|---|
| Company | Curevac N.V. |
| Form Type | 6-K |
| Filed Date | Aug 15, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, collaboration, R&D
TL;DR
CureVac filed a 6-K, showing ongoing work with BioNTech and GSK, plus CRISPR updates.
AI Summary
CureVac N.V. filed a 6-K report on August 15, 2025, for the period ending June 30, 2025. The filing includes information related to its collaborations with BioNTech SE and GlaxoSmithKline, as well as its CRISPR-related activities. Specific financial figures or operational updates beyond these collaborations are not detailed in the provided excerpt.
Why It Matters
This filing provides an update on CureVac's ongoing research and development activities and its partnerships, which are crucial for its future product pipeline and revenue generation.
Risk Assessment
Risk Level: medium — The filing is a routine update, but the nature of biotech R&D and partnerships carries inherent risks.
Key Players & Entities
- CureVac N.V. (company) — Filer of the report
- BioNTech SE (company) — Collaboration partner
- GlaxoSmithKline (company) — Collaboration partner
- CRISPR (technology) — Area of research
FAQ
What is the reporting period for this 6-K filing?
The conformed period of report is June 30, 2025.
When was this 6-K filing submitted?
The filing was submitted on August 15, 2025.
Which companies are mentioned in relation to CureVac's activities?
BioNTech SE and GlaxoSmithKline are mentioned in relation to CureVac's activities.
What specific area of research is highlighted in the filing?
CRISPR-related activities are highlighted in the filing.
What is CureVac N.V.'s fiscal year end?
CureVac N.V.'s fiscal year end is December 31.
Filing Stats: 351 words · 1 min read · ~1 pages · Grade level 11.7 · Accepted 2025-08-15 16:05:39
Filing Documents
- cvac-20250630x6k.htm (6-K) — 107KB
- cvac-20250630xex99d1.htm (EX-99.1) — 739KB
- cvac-20250630xex99d2.htm (EX-99.2) — 221KB
- cvac-20250630xex99d1001.jpg (GRAPHIC) — 10KB
- 0001410578-25-001834.txt ( ) — 4397KB
- cvac-20250630.xsd (EX-101.SCH) — 44KB
- cvac-20250630_cal.xml (EX-101.CAL) — 44KB
- cvac-20250630_def.xml (EX-101.DEF) — 161KB
- cvac-20250630_lab.xml (EX-101.LAB) — 287KB
- cvac-20250630_pre.xml (EX-101.PRE) — 219KB
- cvac-20250630x6k_htm.xml (XML) — 849KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: /s/Axel Sven Malkomes By: /s/Alexander Zehnder Chief Financial Officer Chief Executive Officer Date: August 15, 2025 EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2025 and for the three and six months ended June 30, 2025 and 2024 99.2
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations